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ABSTRACT: Because of their easy access, and important role in oral homeo-
stasis, mammalian salivary glands provide a unique site for addressing key is-
sues and problems in tissue engineering. This manuscript reviews studies by us
in three major directions involving re-engineering functions of salivary epithe-
lial cells. Using adenoviral-mediated gene transfer in vivo, we show approaches
to i) repair damaged, hypofunctional glands and ii) redesign secretory func-
tions to include endocrine as well as exocrine pathways. The third series of
studies show our general approach to develop an artificial salivary gland for
clinical situations in which all glandular tissue has been lost.
INTRODUCTION
An age-old clinical axiom states that the mouth is the gateway to the body. In-
deed, many systemic diseases present with clinical signs easily recognizable in the
open mouth.1 Analogously, the mouth provides several advantages for the applied
scientist or clinician interested in tissue engineering, but none is more important than
ease of access.
For many years, we have been studying mechanisms by which salivary glands
produce their secretions.2,3 Salivary glands have provided a valuable experimental
model for generations of scientists interested in neurofunctional controls, from
Claude Bernard and Ivan Pavlov to the present day. They are highly responsive epi-
thelial tissues whose function can be readily and non-invasively measured.4,5
In humans there are three major pairs of salivary glands (parotid, submandibular,
and sublingual). These glands consist almost entirely of well-differentiated epithe-
lial cells that exist as a monolayer bordering on an extensively arborized lumen.6
Each of these major glands has a direct exit into the mouth through a single main
excretory duct. Thus, from an open mouth the cannulation of the duct orifice, a pro-
cedure which in humans requires no anesthesia, affords direct access to the luminal
membrane of virtually every epithelial cell in this secretory tissue. It is our belief that
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this situation provides a valuable model for addressing several important issues in
tissue engineering. In this manuscript we will review results from two distinct areas
of our tissue-engineering studies: i) the in vivo repair of salivary glands considered
to be irreversibly damaged owing to irradiation and ii) the in vivo redesign of salivary
glands to function in an endocrine capacity. Additionally, we will describe very new
efforts in a third direction, the replacement of destroyed glands with a “first genera-
tion” artificial salivary gland.
GENERAL APPROACH
Our studies directed at in vivo re-engineering of salivary epithelial cells (i.e., for
repair or redesign of function) have utilized replication-deficient recombinant aden-
oviruses to transfer genes into the target cells. After introduction of recombinant ad-
enoviruses to the glands via intraductal delivery through the excretory duct orifice,
these vectors readily infect both ductal and acinar cells in rodent glands, typically
resulting in ∼20–30% of the cells transduced.7,8 While adenoviral vectors are ex-
tremely efficient at transferring genes to, and thus changing the phenotype of, a sal-
ivary cell in vivo, they are not without negative features. The two most significant
drawbacks of recombinant adenoviral vectors are i) their inability to integrate their
DNA into the host cell chromosome and ii) their induction of a potent immune re-
sponse involving innate, cellular and humoral immunity.9,10 As in other parenchy-
mal tissues, the consequence of these drawbacks in salivary glands is the quite
transient expression of the transgene.11,12 Nonetheless, recombinant adenoviral vec-
tors are extremely useful for proof of principle experiments.
Our studies directed at the replacement of destroyed gland tissue utilize more tra-
ditional tissue-engineering concepts.13 Our goal is to create a functional new tissue
using allogeneic graft cells grown and appropriately organized on a suitable biocom-
patible substratum.
IN VIVO GLAND REPAIR
Each year in the U.S. ∼30,000 individuals undergo therapeutic ionizing radiation
to their salivary glands during radiation therapy for head and neck maligancies.14
Acinar cells, the fluid-, salt- and protein-secretory cell type in the glands, are most
sensitive to radiation and are readily destroyed.15 Patients whose salivary glands are
thus rendered hypofunctional suffer from rampant dental caries (decay), frequent
mucosal infections (such as oral Candidiasis), dysphagia (swallowing difficulties),
as well as considerable pain and discomfort. At present, there is no conventional ef-
fective therapy for this condition.
Several years ago, we began examining a strategy which sought to convert the ir-
radiation-surviving absorptive ductal epithelial cells into a secretory, water-perme-
able phenotype. We hypothesized that remaining ductal epithelial cells would be
capable of generating a KHCO3-rich fluid, in the absence of acinar cells, if they are
transduced with (and express) a gene encoding a facilitated water permeability path-
way, a water channel.16 We chose to test this hypothesis by constructing a recombi-
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nant, type 5 adenovirus encoding aquaporin-1 (AQP1).16 AQP1 is the archetypal
mammalian water channel and generally exists in a non-polarized distribution about
the plasma membrane.17 The pivotal experiment tested the ability of the recombinant
virus, termed AdhAQP1, to enhance fluid secretion from rat submandibular glands
which had been exposed 4 months earlier to 21 Gy X-irradiation (TABLE 1). Animals
receiving a control virus showed ∼65% reduction in salivary flow rates when com-
pared to animals that had been sham-irradiated. However, animals receiving
AdhAQP1 after irradiation secreted saliva at control levels.16 Furthermore, the saliva
secreted was significantly higher in [K+] than control saliva, consistent with our hy-
pothesized secretory mechanism.
These results provide considerable encouragement towards the possible utility of
this approach for the effective clinical treatment of patients with radiation-induced
salivary hypofunction. Further, the data are suggestive of the possible re-engineering
of a cellular phenotype in vivo from a non-fluid secreting to a fluid secreting pheno-
type. Our recent work suggests that near maximal, osmotically obligated transepi-
thelial water movement can be realized at low levels of cellular transduction, at least
in an in vitro model system.18 While this general approach, utilizing adenoviral-
mediated gene transfer, is not yet ready for clinical use (especially because of the
transient expression as described above), we believe it represents a significant
achievement. Currently, we are examining the safety and efficacy of the strategy in
a non-human primate model.
IN VIVO GLAND REDESIGN
For much of this century, there have been reports suggesting that salivary glands
were capable of secreting in an endocrine (directly to the bloodstream) as well as
exocrine (saliva to the mouth) manner.19,20 While this is not a widely accepted view,
physiologically, if true it would offer many significant therapeutic opportunities us-
ing gene transfer.21 We directly tested the ability of rat salivary glands to secrete a
foreign transgene product, human α1-antitrypsin (hα1AT), a secretory protein made
in the liver, into the bloodstream. We administered a recombinant adenovirus,
AdMLPhα1AT, to adult rats and measured hα1AT levels in serum, saliva, and gland
extracts.22 We detected hα1AT in all compartments for 4–7 days. On day 4, peak lev-
TABLE 1. Effect of AdhAQP1 on fluid secretion from irradiated rat submandibular
glandsa
Treatment Saliva Flow (µl/100g body weight in 15 min) ± SEM
Sham IR + Addl312 36.6 ± 6.8 (4)
IR + Addl312 12.2 ± 3.7 (6)
IR + AdhAQP1 30.6 ± 3.5 (9)
aData modified from presentation in Delporte et al.16 IR = 21 Gy irradiation. Addl312 is a
control virus encoding no transgene while AdhAQP1 encodes human AQP1. Numbers in paren-
theses = number of animals studied. Irradiation (or sham treatment) was performed and 4 months
later the indicated virus was administered to the submandibular glands. Saliva was collected 3
days later.
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els achieved were ∼5 ng/ml (serum), ∼70 ng/ml (saliva), and ∼10 ng/mg protein
(gland extract). Furthermore, we were able to show that the concentration of hα1AT
in venous blood exiting the gland was consistently higher than that in arterial blood
entering the gland (TABLE 2). These studies unequivocally demonstrated that hα1AT
could be secreted in an endocrine manner from rat salivary glands.22
The hα1AT studies did not, however, demonstrate that the transgene product se-
creted from the glands was functional systemically. Recently, we showed that this
was possible using a different recombinant virus, AdCMVhGH, encoding human
growth hormone (hGH).21 Effective therapeutic levels of GH are ∼5 ng/ml in serum,
comparable to what was achieved with hα1AT. Importantly, hGH can bind to, and
activate, rodent GH receptors. Forty-eight hours after intraductal administration of
AdCMVhGH to rat submandibular glands, serum hGH levels were ∼16 ng/ml versus
background levels of ∼1 ng/ml seen in control rats. We also observed a concomitant
increase in serum insulin-like growth factor levels (∼33%), serum triglycerides
(∼twofold), and the serum BUN/creatinine ratio (∼35%) indicating the hGH secreted
from the salivary glands was physiologically functional and systemically active.
These aggregate results strongly support the notion that salivary glands may pro-
vide a useful target site for the therapeutic delivery of transgene products for system-
ic use. This view also has been supported by the recent studies of Goldfine et al.23
Following the retrograde instillation of plasmid DNA into salivary glands, they ob-
served measurable levels of endocrine hormones in rat serum. Although not yet dem-
onstrated clearly, there appears to be a constitutive secretory routing pathway to the
bloodstream in glandular epithelial cells. However, our studies with hα1AT show
that a transgene product can be secreted simultaneously by both the exocrine (saliva)
and endocrine (serum) pathways. Currently, we are attempting to determine if there
are protein-based sorting signals which we can utilize to direct a transgene product
preferentially into one or the other pathway.
AN ARTIFICIAL SALIVARY GLAND?
There are many patients who effectively have lost all functional salivary epithe-
lium, both acinar and ductal, and experience severe salivary hypofunction. These in-
clude many irradiated patients (above) as well as individuals with Primary Sjögren’s
TABLE 2. Levels of hα1AT in serum from rat submandibular gland arterial and venous
blood after administration of AdMLPhα1ATa
Sample hα1AT (ng/ml)
Carotid Artery 19.4 ± 10.6
Submandibular Vein 67.9 ± 27.2
aData modified from presentation in Kagami et al.22 These represent results (mean ± SEM)
obtained with 7 animals whose right carotid arteries and submandibular veins were sampled 24
hours after admistration of AdMLPhα1AT (5 × 109 pfu) to the right submandibular gland. The
range of hα1AT levels in sera from carotid arteries was 0–70.7 ng/ml, while for sera from sub-
mandibular veins the levels were 5.5–223.4 ng/ml. In each of the 7 animals, the venous level of
hα1AT was greater than the arterial level.
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syndrome, an autoimmune exocrinopathy. In the absence of any glandular epithelial
tissue to manipulate by gene transfer, an alternative patient management strategy is
needed. Although it is possible to transplant mammalian salivary glands,24 this op-
tion would likely prove to be clinically inadequate because of an insufficient donor
supply, the continuous need for immunosuppression, as well as the surgical difficul-
ty. Using well-accepted tissue-engineering principles,13 we are exploring the devel-
opment of an orally implantable, artificial fluid-secreting device, a “first-
generation” artificial salivary gland (FIG. 1).
The initial device which we have envisioned would consist of a blind-end tube
made of a salt and water-permeable, somewhat porous, slowly biodegradable sub-
strate. Previously, while investigating an approach to engineer intestinal tissue,
Mooney et al. reported the construction of a tubular and biodegradable substrate
which promoted vascularization following implantation.25 This type of substrate
could be engineered to contain suitable matrix components necessary to promote the
polarization, growth and organizational behavior of allogeneic graft cells. The graft
cells would be genetically engineered to be capable of unidirectional salt and water
movement in response to autonomic neurotransmitter stimulation.3
Since native salivary epithelia exist essentially as a monolayer lining a lumen,6
the substrate ideally should induce the polarized cells to form a monolayer affording
complete coverage of its internal surface. Such a device also should be small enough
to implant conveniently into the buccal mucosa with a maintained intra-oral exit.
Much of our initial effort has focused on the allogeneic graft cell. We have chosen
to use a human submandibular gland cell line, termed HSG.26 The phenotype of
these cells is known to be highly responsive to different extracellular matrix compo-
nents.27–29 Further, they are useful targets for gene transfer methods7 and can utilize
established salivary gland cell-specific promoter elements.30 Clearly, much addi-
tional work is needed before such an artificial fluid-secreting device can be realized,
but we believe that it is conceptually feasible.
FIGURE 1. Schematic depiction of a first generation artificial salivary gland con-
structed as a blind-end tube. The design requirements for such a device include i) a porous,
slowly biodegradable substratum; ii) matrix components (peptides or macromolecules) that
promote formation of a polarized epithelial cell monolayer; iii) allogeneic epithelial cells
genetically engineered to secrete water and salt unidirectionally; and iv) an overall form eas-
ily implantable in the buccal mucosal with an “exit” to the oral cavity. See text for additional
detail.
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SUMMARY
This manuscript has provided an overview of three directions for our tissue-engi-
neering studies using salivary glands as a model tissue. While salivary glands are not
often considered in tissue-engineering efforts, they present an inviting target because
of their easy access and organizational structure. Additionally, salivary glands suffer
significant clinical disease for which there is no effective conventional therapy avail-
able. We believe that the spectrum of studies reviewed herein demonstrate salivary
glands are valuable models to address key issues and problems in tissue engineering.
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